The short version of melanocortin receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-23 and is reviewed periodically as new material appears.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
== Prognosis == ACC, generally, carries a poor prognosis, with an overall 5-year survival rate of about 50%. Five-year disease-free survival for a complete resection of a stage I–III ACC is about 30%. The most important prognostic factors are age of the patient and stage of the tumor. Poor prognostic factors include mitotic activity, venous invasion, weight of 50 g or more, diameter of 6.5 cm or more, Ki-67/MIB1 labeling index of 4% or more, and p53 positive. In its malignancy, adrenocortical carcinoma is unlike most tumours of the adrenal cortex, which are benign (adenomas) and only occasionally cause Cushing's syndrome.
Army Reserve The Reserve Land Forces regulations 2016 (amendment number 3) Army Reservist Support Service The All-Party Parliamentary Reserve Forces Group – see their most recent report on the TA The Territorial Army 1967–2000 by Wienand Drenth
Frequently acting as an opportunistic, nosocomial pathogen of immunocompromised individuals, but capable of infecting the immunocompetent, P. aeruginosa typically infects the airway, urinary tract, burns, and wounds and also causes other blood infections.
== See also == Asthenia Debility Exercise intolerance § Low ATP reservoir in muscles (inherited or acquired) Fatigue Central fatigue Malaise Metabolic myopathy Myogenic hyperuricemia (due low ATP reservoir in muscle cell) Muscle weakness Paresis
== Expression of Draculin == As a naturally occurring anticoagulant, research into Draculin promises therapeutic strategy into new anticoagulants and provides a foundation for deeper investigations into FXa related coagulation mechanisms. Since the first step of the Draculin-FXa mechanism is driven by concentration and the second step is concentration independent, the FXa-Draculin complex behaves as irreversible under experimental conditions. Glycosylation is a common post-translational modification in which carbohydrates (glycans) are added to proteins or lipids. The resulting glycoproteins and glycolipids acquire altered physical and biochemical properties. As a glycoprotein, Draculin requires a specific glycosylation profile to express its maximum inhibitory activity. Its attached oligosaccharides are essential FXa inhibition, as demonstrated by the loss of anti-Xa activity following incubation with the lectins WGA and PNA.
Sources: en.wikipedia.org
Before Roemer's time in office, Louisiana had no limits on individual campaign contributions, which allowed donors to cut massive checks to campaigns without reporting the contributions. Roemer placed Kennedy in charge of his quest to toughen campaign finance laws, including placing a $5,000 cap on individual contributions to statewide candidates. In addition to ushering in the passage of campaign finance and product liability reforms for Roemer's administration, Kennedy led the effort to consolidate Louisiana's four boards of higher education into one. He said the policy would be "fundamental" to improving Louisiana universities' "quality and desegregation". That effort eventually came one vote short of passage. Roemer lost his reelection bid in 1991, but ran again in 1995 with Kennedy as his campaign manager. Roemer later endorsed Kennedy's bids for Senate. Kennedy remained close to Roemer until his death in 2021 and credited the former governor for getting him involved in public service.
== Further reading == Havelock, H. (April 1898). "The Cossacks in the Early Seventeenth Century". English Historical Review. 13 (50): 242–260. JSTOR 547225. Longworth, Philip (1969). The Cossacks. London: Constable. Seaton, Albert (1985). The Horsemen of the Steppes: The Story of the Cossacks. London: The Bodley Head. ISBN 978-0-370-30534-9. Summerfield, Stephen (2005). Cossack Hurrah: Russian Irregular Cavalry Organisation and Uniforms during the Napoleonic Wars. Partizan Press. ISBN 978-1-85818-513-2. Summerfield, Stephen (2007). The Brazen Cross: Brazen Cross of Courage: Russian Opochenie, Partizans and Russo-German Legion during the Napoleonic Wars. Partizan Press. ISBN 978-1-85818-555-2. Ure, John (1999). The Cossacks. London: Constable. ISBN 978-0-094-77400-1. Witzenrath, Christoph (2007). Cossacks and the Russian Empire, 1598–1725: Manipulation, Rebellion and Expansion into Siberia. Routledge. ISBN 978-1-134-11749-9. "General der Flieger Hellmuth Felmy" [The Cossack Corps]. US Army Historical Division. Hailer Publishing. 2007. Archived from the original on 2009-04-15. Kondufor, Yuri (1986). A Short History of the Ukraine. Kyiv: Naukova Dumka.
=== Compression gloves === Compression gloves are handwear designed to help prevent the occurrence of various medical disorders relating to blood circulation in the wrists and hands. They can be used to treat the symptoms of arthritis, though the medical benefits may be limited.
Birds play prominent and diverse roles in religion and mythology. In religion, birds may serve as either messengers or priests and leaders for a deity, such as in the Cult of Makemake, in which the Tangata manu of Easter Island served as chiefs or as attendants, as in the case of Hugin and Munin, the two common ravens who whispered news into the ears of the Norse god Odin. In several civilisations of ancient Italy, particularly Etruscan and Roman religion, priests were involved in augury, or interpreting the words of birds while the "auspex" (from which the word "auspicious" is derived) watched their activities to foretell events. They may also serve as religious symbols, as when Jonah (Hebrew: יונה, dove) embodied the fright, passivity, mourning, and beauty traditionally associated with doves. Birds have themselves been deified, as in the case of the common peacock, which is perceived as Mother Earth by the people of southern India. In the ancient world, doves were used as symbols of the Mesopotamian goddess Inanna (later known as Ishtar), the Canaanite mother goddess Asherah, and the Greek goddess Aphrodite. In ancient Greece, Athena, the goddess of wisdom and patron deity of the city of Athens, had a little owl as her symbol. In religious images preserved from the Inca and Tiwanaku empires, birds are depicted in the process of transgressing boundaries between earthly and underground spiritual realms. Indigenous peoples of the central Andes maintain legends of birds passing to and from metaphysical worlds.
==== Rape Accusations ==== On May 11, 2004, The Boston Globe covered a press conference by Boston City Councilor Chuck Turner and local civil rights activist Sadiki Kambon during which they distributed photographs they alleged showed American soldiers raping Iraqi woman. In its early editions on May 12, photographs from the event clearly showed some of the pictures presented, the Globe later apologized for the error. Other news agencies quickly responded to the story by linking the photographs to American and Hungarian pornography sites. Several sources stated that Iraqi females, including teenage girls, were sexually assaulted while being detained at Abu Ghraib and other US military detention facilities across Iraq. American journalist Tara McKelvey, writing for the magazine The American Prospect, interviewed an Iraqi sheik in the fall of 2004 about this issue and he told her that "he had seen a young girl, 15 years old, with internal bleeding. She had been raped over and over again by the soldiers, and she could no longer talk. He is a deeply religious man. But that night, he shouted at Allah. ‘How is it possible that you are there and these things are happening?!' he said.”
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.